- Global Pharma News & Resources

MOLOGEN AG: Sale of the essential assets

MOLOGEN AG / Key word(s): Insolvency
MOLOGEN AG: Sale of the essential assets

08-May-2020 / 12:44 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Mologen AG - Sale of the essential assets

The insolvency administrator of Mologen AG (WKN A2LQ90) has accepted the offer to sell a substantial part of Mologen's assets (in particular delvopments associated with Lefitolimod and Enandim) to Gilead Sciences Inc. The purchase price will probably enable a dividend for creditors in the insolvency but will not be sufficient to satisfy all insolvency claims in full.


Please note: Claims arising from the convertible bonds 2016/2024 and 2017/2025 can only be filed through the joint representative of the bondholders, Dr. Marc Liebscher, c/o Dr. Späth & Partner Rechtsanwälte, Kurfürstendamm 102, 10711 Berlin."

Christian Köhler-Ma
Insolvenzverwalter der Mologen AG
Potsdamer Platz 1
10785 Berlin,
030 / 700 171 500

08-May-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Königin-Luise-Str. 27
14195 Berlin
Phone: 030 / 841788-0
Fax: 030 / 841788-50
ISIN: DE000A2LQ900
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1039707

End of Announcement DGAP News Service

Editor Details

Last Updated: 08-May-2020